(Q37692420)

English

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials

scientific article published on April 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 August 2017

0 references

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

22 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

thromboembolism

1 reference

based on heuristic

inferred from title

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

author name string

Vishal Ranpura

1

1 reference

Europe PubMed Central

22 August 2017

Sanjaykumar Hapani

2

1 reference

Europe PubMed Central

22 August 2017

Jeff Chuang

3

1 reference

Europe PubMed Central

22 August 2017

Shenhong Wu

4

1 reference

Europe PubMed Central

22 August 2017

publication date

1 April 2010

1 reference

Europe PubMed Central

22 August 2017

Acta Oncologica

1 reference

Europe PubMed Central

22 August 2017

49

1 reference

Europe PubMed Central

22 August 2017

3

1 reference

Europe PubMed Central

22 August 2017

287-297

1 reference

Europe PubMed Central

22 August 2017

Molecular mechanisms of tumor angiogenesis and tumor progression

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Managing patients treated with bevacizumab combination therapy.

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Selecting and appraising studies for a systematic review

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Quantitative synthesis in systematic reviews

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab, bleeding, thrombosis, and warfarin

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA.

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Arterial and venous thrombotic complications with thalidomide in multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Arterial thrombosis in four patients treated with thalidomide

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F02841860903524396

21 January 2018

Identifiers

10.3109/02841860903524396

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37692420&oldid=2043622340"